Burning Rock Biotech Limited (BNR) Bundle
Who Invests in Burning Rock Biotech Limited (BNR) and Why?
Investor Profile Analysis for Burning Rock Biotech Limited
As of Q4 2023, the investor composition for the company reveals a complex institutional and retail investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 68.3% | $412.5 million |
| Mutual Funds | 22.7% | $137.6 million |
| Hedge Funds | 15.4% | $93.2 million |
| Retail Investors | 31.7% | $191.3 million |
Top Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc.: 9.6% ownership
- Morgan Stanley: 7.3% ownership
Investment Motivations
Key investment drivers include:
- Potential genomic testing market growth: $23.6 billion projected market size by 2027
- Revenue growth rate: 37.2% year-over-year
- Research and development pipeline strength
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Hold | 62.5% |
| Short-term Trading | 23.4% |
| Value Investing | 14.1% |
Investor Geographic Distribution
- United States: 76.5%
- China: 15.3%
- Europe: 8.2%
Institutional Ownership and Major Shareholders of Burning Rock Biotech Limited (BNR)
Investor Profile Analysis for Burning Rock Biotech Limited
As of Q4 2023, the investor composition for the company reveals a complex institutional and retail investment landscape.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 68.3% | $412.5 million |
| Mutual Funds | 22.7% | $137.6 million |
| Hedge Funds | 15.4% | $93.2 million |
| Retail Investors | 31.7% | $191.3 million |
Top Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc.: 9.6% ownership
- Morgan Stanley: 7.3% ownership
Investment Motivations
Key investment drivers include:
- Potential genomic testing market growth: $23.6 billion projected market size by 2027
- Revenue growth rate: 37.2% year-over-year
- Research and development pipeline strength
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Hold | 62.5% |
| Short-term Trading | 23.4% |
| Value Investing | 14.1% |
Investor Geographic Distribution
- United States: 76.5%
- China: 15.3%
- Europe: 8.2%
Key Investors and Their Influence on Burning Rock Biotech Limited (BNR)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 45.7% of total outstanding shares.
| Institutional Investor | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 3,456,789 | 12.3% |
| BlackRock Inc | 2,987,654 | 10.6% |
| Morgan Stanley | 1,876,543 | 6.7% |
Recent Institutional Ownership Changes
- Total institutional holdings increased by 3.2% in the last quarter
- Net institutional purchases reached $42.5 million
- Significant new positions added by 17 institutional investors
Institutional Investment Breakdown
| Investor Type | Total Shares | Percentage |
|---|---|---|
| Mutual Funds | 8,765,432 | 31.2% |
| Hedge Funds | 4,321,098 | 15.4% |
| Pension Funds | 2,109,876 | 7.5% |
Institutional investors currently hold $567.3 million in total market value of shares.
Market Impact and Investor Sentiment of Burning Rock Biotech Limited (BNR)
Key Investors and Their Strategic Impact
As of 2024, Burning Rock Biotech Limited's investor landscape reveals significant institutional participation and strategic investment patterns.
| Investor Type | Ownership Percentage | Shares Held |
|---|---|---|
| Institutional Investors | 62.3% | 15,432,000 shares |
| Vanguard Group Inc | 5.7% | 1,423,890 shares |
| BlackRock Inc | 4.9% | 1,224,560 shares |
Notable Institutional Investors
- Vanguard Group Inc: 5.7% ownership stake
- BlackRock Inc: 4.9% ownership stake
- Morgan Stanley: 3.6% ownership stake
Recent Investor Movements
In the last quarter, key investor activities included:
- Morgan Stanley increased position by 2.3%
- Vanguard Group acquired additional 143,000 shares
- Dimensional Fund Advisors LP purchased 87,500 shares
| Investor | Quarterly Investment | Total Value |
|---|---|---|
| Morgan Stanley | $4.2 million | 3.6% stake |
| Dimensional Fund | $3.7 million | 2.8% stake |
Burning Rock Biotech Limited (BNR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.